HEALTH● LOWAug 13 · Aug 13, 2026, 11:18 PM
Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance
Seeking Alpha Tech
Belite Bio has received FDA priority review acceptance for Tinlarebant in Stargardt disease, with a PDUFA date set for February 12, 2027. This marks a key milestone in the drug's development and potential availability for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h ago The health system in Nepal is not prepared for this upr.org · United StatesHEALTH1h agoEmotional Resilience with ADHD : Coping with Dysregulated Feelingsadditudemag.com · United StatesHEALTH1h agoBradley Riches Shares His Story of Surviving a Suicide Attemptinstinctmagazine.com · United StatesHEALTH1h agoHigh TDS , bad taste or borewell water ? Dont buy a purifier until you know thislivemint.com · India